이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발 또는 불응성 다발성 골수종 환자를 대상으로 한 IBI3003 연구

2026년 9월 22일 업데이트: Fortvita Biologics (USA)Inc.

재발성 또는 불응성 다발성 골수종 환자를 대상으로 한 IBI3003의 1/2상, 다기관, 개방형 연구

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

연구 개요

상태

모병

개입 / 치료

연구 유형

중재적

등록 (추정된)

360

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Arizona
      • Scottsdale, Arizona, 미국, 85258
        • 모집하지 않고 적극적으로
        • Honor Health
    • California
      • Duarte, California, 미국, 91010
      • Irvine, California, 미국, 92618
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모집하지 않고 적극적으로
        • Emory
    • New York
      • New York, New York, 미국, 10021
    • Texas
      • Houston, Texas, 미국, 77030

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

Participants in Parts 1 & 2 must satisfy all of the following criteria to be enrolled in the study:

  1. Age ≥18 years.

  2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.

    Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of the following myelomadefining events:

    • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or corrected serum calcium >2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
    • Any one or more of the following biomarkers of malignancy:

    Clonal bone marrow plasma cell percentage ≥60% Involved: uninvolved serum free light chain ratio ≥100 (involved FLC level must be

    ≥100 mg/L) >1 focal lesions on MRI studies (at least 5 mm in size)

  3. Relapsed or refractory measurable multiple myeloma (R/R MM) following prior treatment with ≥3 lines of systemic anti-myeloma therapy that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy, and with limited or no therapeutic options that are likely to offer a favorable risk/benefit profile; participants must be relapsed or refractory to their last anti-myeloma regimen.

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

  5. At least one of the following measurable disease indicators:

    • Serum M-protein ≥5 g/L (for IgA and IgD subtypes, quantitative immunoglobin measurements could be used as substitutions for M-protein)
    • Urine M-protein ≥200 mg/24h
    • Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (<0.26 or >1.65)
  6. Adequate hematologic, hepatic, renal and cardiac function:

    • Blood count: absolute neutrophil count ≥1.0×10^9/L, hemoglobin ≥70 g/L, and platelet count ≥50×10^9/L (values must be achieved without growth factors or blood transfusions within 7 days prior to first dose)
    • Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤2.5× upper limit of normal (ULN) and total bilirubin (TBIL) ≤1.5×ULN
    • Renal function: calculated creatinine ≥30 mL/min by the Cockcroft-Gault Equation
    • Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%
  7. Life expectancy ≥3 months.

  8. Women of childbearing potential and fertile men who are sexually active must agree to use a highly effective method of contraception (<1% / year failure rate) during the study and for 90 days after the last dose level of study drug. Contraception must be consistent with local regulations or standards regarding the use of birth control methods by participants participating in clinical trials. Women and men must agree not to donate or bank eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose level of study drug.

  9. Participants with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

  10. Willing and able to adhere to the complete schedule of assessments and all prohibitions and restrictions specified in this protocol

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.

  2. Active amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or solitary plasmacytoma, or smoldering multiple myeloma (MM) as defined by the IMWG criteria.

  3. Spinal cord compression that results in limited self-care at present or within 6 months prior to informed consent, or that is expected to cause such limitations during Study participation.

  4. History of primary immunodeficiency.

  5. Current or previous other malignancy within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.

  6. Allogeneic hematopoietic stem cell transplantation within the last 6 months, or autologous stem cell transplantation within the last 3 months prior to the first administration of the study drug.

  7. History of organ transplantation.

  8. Active graft-versus-host disease.

  9. Thromboembolism or cerebrovascular events (e.g., myocardial infarction, unstable angina, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with complications of central venous access], or pulmonary embolism) within 6 months prior to the first dose of study drug.

  10. Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.

  11. Known allergies, hypersensitivity, or intolerance to IBI3003 or its excipients (refer to Investigator's Brochure).

  12. Prior toxicities that have not resolved to ≤Grade 1 prior to study treatment administration except for stable chronic toxicities (≤Grade 2) not expected to resolve (e.g., stable Grade 2 peripheral neurotoxicity)

  13. Prior antitumor therapy as follows, prior to the first dose of study drug:

    • Gene modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, natural killer cells) within 8 weeks.
    • Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer.
    • Antibody treatment (e.g., monoclonal antibody, bispecific antibody) for multiple myeloma within 21 days.
    • Cytotoxic therapy (including antibody-drug conjugates) within 14 days.
    • Proteasome inhibitor therapy within 14 days Immunomodulatory agent therapy within 7 days.
    • Radiotherapy within 21 days. However, if the radiation field covered ≤5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy.
    • Cancer vaccine received within 3 months.
  14. Use of immunosuppressive therapy within 28 days of the start date of study treatment.

    Immunosuppressive therapy includes, but is not limited to, cyclosporine A, tacrolimus, and mycophenolate mofetil, but does not include corticosteroids given as part of an antimyeloma regimen. Participants receiving corticosteroids must be at a dose level ≤10 mg/day of prednisone equivalent for at least 7 days prior to the start of study treatment administration.

  15. Live or live attenuated vaccine administered within 4 weeks prior to start of study treatment, or anticipated need for live or live attenuated vaccine during the study.

  16. Uncontrolled diseases, including:

    • Uncontrolled infection or infection requiring systemic antibiotics, antivirals or antifungals within one week prior to first administration of the study drug;
    • Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
    • For participants in mainland China, acute or chronic active hepatitis B (HBsAg positive and/or HBcAb positive with HBV DNA titer ≥104 copies/mL or ≥2000 IU/mL) or C (HCV Ab positive with HCV RNA>103 copies/mL). For participants outside of mainland China, active, latent or incompletely treated infection with HBV or HCV;
    • Failed to complete anti-tuberculosis therapy at any point prior to C1D1; active tuberculosis infection, or still on anti-tuberculosis therapy;
    • Active syphilis infection requiring treatment;
    • Symptomatic congestive heart failure Grade II-IV (New York Heart Association [NYHA]), symptomatic or uncontrolled arrhythmias, QTc interval (calculate using the Fridericia formula) >480 ms, or personal or family history of congenital long/short QT syndrome;
    • Uncontrollable hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg);
    • Active autoimmune diseases, including but not limited to inflammatory bowel disease, autoimmune hepatitis, demyelinating lesions, extensive dermatitis, immunerelated interstitial pneumonia, or Grave's disease requiring antithyroid medication control (vitiligo, or hypothyroidism requiring hormone replacement therapy, type I diabetes requiring only insulin replacement therapy and no other systemic therapy in the past 2 years are eligible); Presence of clinically uncontrolled pleural/peritoneal effusions (participants who do not require regular drainage or who do not demonstrate significant re-accumulation of effusion for at least 72 hours after the most recent drainage can enroll).
  17. Major surgery within 2 weeks prior to the first dose of study treatment, not fully recovered from any prior surgery, or has non-minor surgery anticipated during the time the participant is expected to receive study drug or within 2 weeks after the last dose of study drug administration.

  18. Participating in any other interventional clinical research except an observational (noninterventional) study or the survival follow-up phase of an interventional study.

  19. Currently pregnant or breastfeeding.

  20. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

  21. Inability to comprehend or unwilling to sign the ICF

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: IBI3003

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adverse events (AEs)
기간: Up to 30 days post last dose

Number of patients who Experienced related AEs from the first dose until 30 days after the last dose

Up to 30 days post last dose
Dose limiting toxicities (DLTs)
기간: Up to 28 days post first dose

To evaluate the safety and tolerability of IBI3003

Up to 28 days post first dose
ORR
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003
기간: up to 24 months

To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003

up to 24 months

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence and characterization of anti-drug antibody (ADA).
기간: up to 24 months

To evaluate the immunogenicity of IBI3003

up to 24 months
Preliminary efficacy including objective response rate (ORR)
기간: up to 24 months

objective response rate. To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To evaluate minimal residual disease (MRD) negativity rates. MRD negativity rate.
기간: up to 24 months

To evaluate minimal residual disease (MRD) negativity rates.

up to 24 months
efficacy estimates sCRR
기간: up to 24 months

stringent complete response rate. To evaluate other efficacy estimates of IBI3003 in the participant population.

up to 24 months
Incidence of TEAEs
기간: up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
half-life (T1/2)
기간: up to 24 months

To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
time to maximum concentration (Tmax)
기간: up to 24 months

time to peak concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
maximum concentration (Cmax)
기간: peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months

peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.
area under the curve (AUC)
기간: up to 24 months

area under the curve. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
complete response rate (CRR)
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
very good partial response rate (VGPRR)
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
duration of response (DoR)
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
disease control rate (DCR)
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
time to response (TTR)
기간: To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.
progression free survival (PFS).
기간: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
SAEs
기간: up to 24 months

serious adverse events (SAEs) Adverse events will be assessed by investigator(s) To evaluate the safety of IBI3003 in the participant population.

up to 24 months
changes in laboratory parameters
기간: up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
physical examination findings
기간: up to 24 months

A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.To evaluate the safety of IBI3003 in the participant population.

up to 24 months
vital signs
기간: up to 24 months

Collection of vital signs will include temperature in ℃, measurement tool is physiological parameter.To evaluate the safety of IBI3003 in the participant population.

up to 24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 30일

기본 완료 (추정된)

2027년 6월 30일

연구 완료 (추정된)

2028년 9월 30일

연구 등록 날짜

최초 제출

2026년 1월 8일

QC 기준을 충족하는 최초 제출

2026년 1월 12일

처음 게시됨 (실제)

2026년 1월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다